Drug profile · INN
rucaparib camsylate
RUBRACA
rucaparib camsylate (RUBRACA) is a parp 1, 2 and 3 inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — rucaparib camsylate
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 2
- Data quality
- 0.84
Quick answer
rucaparib camsylate (RUBRACA) is a parp 1, 2 and 3 inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
PARP 1, 2 and 3 inhibitor
Primary target: PARP 1, 2 and 3
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is rucaparib camsylate?
rucaparib camsylate (RUBRACA) is a parp 1, 2 and 3 inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for rucaparib camsylate?
RUBRACA is a marketed brand name for rucaparib camsylate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of rucaparib camsylate?
rucaparib camsylate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.